Nichi Glucan

GN Corporation is a Japanese biotechnology company specializing in the development and commercialization of unique biological response modifier (BRM) products, most notably the Nichi Glucan range. The company's core technology involves the production of Beta-1,3-1,6-glucans derived from the black yeast Aureobasidium pullulans (strains AFO-202 and N-163), which are marketed as food supplements with potent immunomodulatory properties. Beyond nutraceuticals, GN Corporation is active in regenerative medicine, developing cell culture scaffolds and collaborating on clinical research for indications ranging from oncology and metabolic disorders to viral infections like COVID-19. The company operates through a global network, particularly through its long-standing partnership with Nichi-In Bio Sciences, to bridge Japanese innovation with international clinical applications.